Predictive MRI Biomarkers in MS-A Critical Review

Overview

Journal Medicina (Kaunas)

Publisher MDPI

Specialty General Medicine

Date 2022 Mar 26

PMID 35334554

Authors

Vlad Eugen Tiu

Iulian Enache

Cristina Aura Panea

Cristina Tiu

Bogdan Ovidiu Popescu

Affiliations

Soon will be listed here.

Abstract

In this critical review, we explore the potential use of MRI measurements as prognostic biomarkers in multiple sclerosis (MS) patients, for both conventional measurements and more novel techniques such as magnetization transfer, diffusion tensor, and proton spectroscopy MRI. All authors individually and comprehensively reviewed each of the aspects listed below in PubMed, Medline, and Google Scholar. There are numerous MRI metrics that have been proven by clinical studies to hold important prognostic value for MS patients, most of which can be readily obtained from standard 1.5T MRI scans. While some of these parameters have passed the test of time and seem to be associated with a reliable predictive power, some are still better interpreted with caution. We hope this will serve as a reminder of how vast a resource we have on our hands in this versatile tool-it is up to us to make use of it.

Citing Articles

Primary Progressive Multiple Sclerosis-A Key to Understanding and Managing Disease Progression.

Sempik I, Dziadkowiak E, Moreira H, Zimny A, Pokryszko-Dragan A Int J Mol Sci. 2024; 25(16).

PMID: 39201438 PMC: 11354232. DOI: 10.3390/ijms25168751.

Predictors of multiple sclerosis progression: A systematic review of conventional magnetic resonance imaging studies.

Lomer N, AmirAshjei Asalemi K, Saberi A, Sarlak K PLoS One. 2024; 19(4):e0300415.

PMID: 38626023 PMC: 11020451. DOI: 10.1371/journal.pone.0300415.

2.5-Year changes of connectivity dynamism are relevant for physical and cognitive deterioration in multiple sclerosis.

Rocca M, dAmore G, Valsasina P, Tedone N, Meani A, Filippi M Mult Scler. 2024; 30(4-5):546-557.

PMID: 38372039 PMC: 11010569. DOI: 10.1177/13524585241231155.

Prognostic relevance of MRI in early relapsing multiple sclerosis: ready to guide treatment decision making?.

Hoffmann O, Gold R, Meuth S, Linker R, Skripuletz T, Wiendl H Ther Adv Neurol Disord. 2024; 17:17562864241229325.

PMID: 38332854 PMC: 10851744. DOI: 10.1177/17562864241229325.

Serum Neurofilaments and OCT Metrics Predict EDSS-Plus Score Progression in Early Relapse-Remitting Multiple Sclerosis.

Tiu V, Popescu B, Enache I, Tiu C, Cherecheanu A, Panea C Biomedicines. 2023; 11(2).

PMID: 36831142 PMC: 9953670. DOI: 10.3390/biomedicines11020606.

References

Audoin B, Ibarrola D, Malikova I, Soulier E, Confort-Gouny S, Duong M . Onset and underpinnings of white matter atrophy at the very early stage of multiple sclerosis--a two-year longitudinal MRI/MRSI study of corpus callosum. Mult Scler. 2007; 13(1):41-51. DOI: 10.1177/1352458506071215. View

Jasperse B, Valsasina P, Neacsu V, Knol D, De Stefano N, Enzinger C . Intercenter agreement of brain atrophy measurement in multiple sclerosis patients using manually-edited SIENA and SIENAX. J Magn Reson Imaging. 2007; 26(4):881-5. DOI: 10.1002/jmri.21101. View

Wagner S, Adams H, Sobel D, Slivka L, Sipe J, Romine J . New hypointense lesions on MRI in relapsing-remitting multiple sclerosis patients. Eur Neurol. 2000; 43(4):194-200. DOI: 10.1159/000008175. View

Liu Z, Pardini M, Yaldizli O, Sethi V, Muhlert N, Wheeler-Kingshott C . Magnetization transfer ratio measures in normal-appearing white matter show periventricular gradient abnormalities in multiple sclerosis. Brain. 2015; 138(Pt 5):1239-46. PMC: 5963416. DOI: 10.1093/brain/awv065. View

Rieckmann P, Traboulsee A, Devonshire V, Oger J . Escalating immunotherapy of multiple sclerosis. Ther Adv Neurol Disord. 2010; 1(3):181-92. PMC: 3002550. DOI: 10.1177/1756285608098359. View

Sarbu N, Shih R, Jones R, Horkayne-Szakaly I, Oleaga L, Smirniotopoulos J . White Matter Diseases with Radiologic-Pathologic Correlation. Radiographics. 2016; 36(5):1426-47. DOI: 10.1148/rg.2016160031. View

Llufriu S, Kornak J, Ratiney H, Oh J, Brenneman D, Cree B . Magnetic resonance spectroscopy markers of disease progression in multiple sclerosis. JAMA Neurol. 2014; 71(7):840-7. DOI: 10.1001/jamaneurol.2014.895. View

Swanton J, Fernando K, Miller D . Early prognosis of multiple sclerosis. Handb Clin Neurol. 2014; 122:371-91. DOI: 10.1016/B978-0-444-52001-2.00015-7. View

Zivadinov R, Dwyer M, Barkay H, Steinerman J, Knappertz V, Khan O . Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense "black holes": a post hoc magnetic resonance imaging analysis. J Neurol. 2014; 262(3):648-53. DOI: 10.1007/s00415-014-7616-0. View

10.

Inglese M, Bester M . Diffusion imaging in multiple sclerosis: research and clinical implications. NMR Biomed. 2010; 23(7):865-72. PMC: 3071990. DOI: 10.1002/nbm.1515. View

11.

Geurts J, Calabrese M, Fisher E, Rudick R . Measurement and clinical effect of grey matter pathology in multiple sclerosis. Lancet Neurol. 2012; 11(12):1082-92. DOI: 10.1016/S1474-4422(12)70230-2. View

12.

Klistorner S, Barnett M, Yiannikas C, Barton J, Parratt J, You Y . Expansion of chronic lesions is linked to disease progression in relapsing-remitting multiple sclerosis patients. Mult Scler. 2020; 27(10):1533-1542. DOI: 10.1177/1352458520974357. View

13.

Traboulsee A, Dehmeshki J, Peters K, Griffin C, Brex P, Silver N . Disability in multiple sclerosis is related to normal appearing brain tissue MTR histogram abnormalities. Mult Scler. 2003; 9(6):566-73. DOI: 10.1191/1352458503ms958oa. View

14.

van Waesberghe J, van Walderveen M, Castelijns J, Scheltens P, Lycklama A Nijeholt G, Polman C . Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. AJNR Am J Neuroradiol. 1998; 19(4):675-83. PMC: 8337386. View

15.

Radue E, Barkhof F, Kappos L, Sprenger T, Haring D, de Vera A . Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis. Neurology. 2015; 84(8):784-93. PMC: 4339126. DOI: 10.1212/WNL.0000000000001281. View

16.

Pisani A, Scalfari A, Crescenzo F, Romualdi C, Calabrese M . A novel prognostic score to assess the risk of progression in relapsing-remitting multiple sclerosis patients. Eur J Neurol. 2021; 28(8):2503-2512. PMC: 8360167. DOI: 10.1111/ene.14859. View

17.

Tintore M, Rovira A, Arrambide G, Mitjana R, Rio J, Auger C . Brainstem lesions in clinically isolated syndromes. Neurology. 2010; 75(21):1933-8. DOI: 10.1212/WNL.0b013e3181feb26f. View

18.

Rocca M, Battaglini M, Benedict R, De Stefano N, Geurts J, Henry R . Brain MRI atrophy quantification in MS: From methods to clinical application. Neurology. 2016; 88(4):403-413. PMC: 5272969. DOI: 10.1212/WNL.0000000000003542. View

19.

Bo L, Geurts J, Mork S, van der Valk P . Grey matter pathology in multiple sclerosis. Acta Neurol Scand Suppl. 2006; 183:48-50. DOI: 10.1111/j.1600-0404.2006.00615.x. View

20.

Uher T, Bergsland N, Krasensky J, Dwyer M, Andelova M, Sobisek L . Interpretation of Brain Volume Increase in Multiple Sclerosis. J Neuroimaging. 2020; 31(2):401-407. DOI: 10.1111/jon.12816. View